Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry studyEuropean Journal of Nuclear Medicine and Molecular ImagingIF7.62023-12-016OAAI
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor TherapyANNALS OF HEMATOLOGYIF2.42014-04-0425PREAI
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group For Medical Tumor Therapy (vol 75, pg 135, 1997)ANNALS OF HEMATOLOGYIF2.42013-12-181PREAI
Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US OncologyANNALS OF ONCOLOGYIF65.42012-07-0162OA
Rates and risk of pneumonitis in non-small cell lung carcinoma (NSCLC) patients (pts) treated with concurrent chemoradiationINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICSIF6.52008-09-012PREAI
Efficacy and toxicity of 2-chlorodeoxyadenosine (Cladribine) -: 2 h Infusion for 5 days -: as first-line treatment for advanced low grade non-Hodgkin's lymphomaEUROPEAN JOURNAL OF CANCERIF7.11998-09-0125PREAI